News

Explore latest news and insights on influential business leaders from around the world. Get exclusive interviews, and in-depth coverage of top executives, entrepreneurs, and innovators on Fox ...
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of ...